When I first invested it was for HIV. The science
Post# of 148117
The risks were immense. And my initial investment was small. The share price ground down under 50 cents on dilution. But more and more data came out in other indications that a ccr5 antagonist could treat. As more indications presented, I increased my holding. Once cancer became a likely target I invested a large chunk of money directly with the company in order to get warrants in addition to my shares.
It wasn't a guess. A gamble? Maybe. But a well educated one at that.